KURA ONCOLOGY, INC. Increase (Decrease) in Accounts Receivable
KURA ONCOLOGY, INC. (KURA) reported Increase (Decrease) in Accounts Receivable of $642.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-12
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $98.00K.
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $544.00K, a 98.83% decline year-over-year.
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was -$44.17M.
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $46.69M.
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2025 was $6.74M, a 227.38% increase from fiscal 2024.
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2024 was $2.06M.
- KURA ONCOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|
| 2026-06-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $642.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $544.00K 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | $6.74M 10-K · filed 2026-03-05 | ||
| 2025-06-30 | -$44.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.51M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $46.69M 10-Q · filed 2026-05-12 | ||
| 2024-12-31 | $2.06M 10-K · filed 2026-03-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |